| Variable . | No major bleed (N = 6830; 92.2%) . | Major bleed (N = 581; 7.8%) . | P-value** . |
|---|---|---|---|
| Demographics | |||
| Age (years) (median) IQR | 75 (67–81) | 78 (71–83) | <0.0001 |
| Male gender | 57.9 | 53.9 | 0.06 |
| White race | 89.4 | 91.6 | 0.06 |
| Comorbidities | |||
| Anaemia/abnormal Hgb/Hct | 34.8 | 57.5 | <0.0001 |
| Hypertension | 84.5 | 89.3 | 0.0019 |
| Diabetes | 30.3 | 33.7 | 0.08 |
| Current smoker | 5.3 | 6.5 | <0.0001 |
| GI bleed | 7.4 | 15.5 | <0.0001 |
| Prior stroke | 9.2 | 13.1 | 0.002 |
| CHF | 33.8 | 44.9 | <0.0001 |
| MI | 15.4 | 20.5 | 0.001 |
| Osteoporosis/hip fracture | 14.4 | 20.3 | 0.0001 |
| COPD | 15.7 | 24.4 | <0.0001 |
| History of cancer | 23.3 | 30.8 | <0.0001 |
| Antithrombotic therapy | |||
| Antiplatelets | 37.0 | 49.1 | <0.0001 |
| Warfarin | 93.4 | 95.0 | 0.14 |
| Dabigatran | 6.6 | 5.2 | 0.18 |
| eGFR<60 mg/dL/1.73 m2 | 34.0 | 48.4 | <0.0001 |
| CHA2DS2-VASC, median (IQR) | 4.0 (3.0–5.0) | 5.0 (4.0–6.0) | <0.0001 |
| HAS-BLED, median (IQR) | 2.0 (1.0–2.0) | 2.0 (2.0–3.0) | <0.0001 |
| ATRIA bleeding score, median (IQR) | 3.0 (1.0–4.0) | 4.0 (3.0–6.0) | <0.0001 |
| Variable . | No major bleed (N = 6830; 92.2%) . | Major bleed (N = 581; 7.8%) . | P-value** . |
|---|---|---|---|
| Demographics | |||
| Age (years) (median) IQR | 75 (67–81) | 78 (71–83) | <0.0001 |
| Male gender | 57.9 | 53.9 | 0.06 |
| White race | 89.4 | 91.6 | 0.06 |
| Comorbidities | |||
| Anaemia/abnormal Hgb/Hct | 34.8 | 57.5 | <0.0001 |
| Hypertension | 84.5 | 89.3 | 0.0019 |
| Diabetes | 30.3 | 33.7 | 0.08 |
| Current smoker | 5.3 | 6.5 | <0.0001 |
| GI bleed | 7.4 | 15.5 | <0.0001 |
| Prior stroke | 9.2 | 13.1 | 0.002 |
| CHF | 33.8 | 44.9 | <0.0001 |
| MI | 15.4 | 20.5 | 0.001 |
| Osteoporosis/hip fracture | 14.4 | 20.3 | 0.0001 |
| COPD | 15.7 | 24.4 | <0.0001 |
| History of cancer | 23.3 | 30.8 | <0.0001 |
| Antithrombotic therapy | |||
| Antiplatelets | 37.0 | 49.1 | <0.0001 |
| Warfarin | 93.4 | 95.0 | 0.14 |
| Dabigatran | 6.6 | 5.2 | 0.18 |
| eGFR<60 mg/dL/1.73 m2 | 34.0 | 48.4 | <0.0001 |
| CHA2DS2-VASC, median (IQR) | 4.0 (3.0–5.0) | 5.0 (4.0–6.0) | <0.0001 |
| HAS-BLED, median (IQR) | 2.0 (1.0–2.0) | 2.0 (2.0–3.0) | <0.0001 |
| ATRIA bleeding score, median (IQR) | 3.0 (1.0–4.0) | 4.0 (3.0–6.0) | <0.0001 |
IQR, interquartile range; hgb, haemoglobin; hct, haematocrit; GI, gastrointestinal; CHF, congestive heart failure; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate.
aPer cent or value.
**P-values from chi-squared tests for categorical variables and Kruskal–Wallis tests for continuous variables.
| Variable . | No major bleed (N = 6830; 92.2%) . | Major bleed (N = 581; 7.8%) . | P-value** . |
|---|---|---|---|
| Demographics | |||
| Age (years) (median) IQR | 75 (67–81) | 78 (71–83) | <0.0001 |
| Male gender | 57.9 | 53.9 | 0.06 |
| White race | 89.4 | 91.6 | 0.06 |
| Comorbidities | |||
| Anaemia/abnormal Hgb/Hct | 34.8 | 57.5 | <0.0001 |
| Hypertension | 84.5 | 89.3 | 0.0019 |
| Diabetes | 30.3 | 33.7 | 0.08 |
| Current smoker | 5.3 | 6.5 | <0.0001 |
| GI bleed | 7.4 | 15.5 | <0.0001 |
| Prior stroke | 9.2 | 13.1 | 0.002 |
| CHF | 33.8 | 44.9 | <0.0001 |
| MI | 15.4 | 20.5 | 0.001 |
| Osteoporosis/hip fracture | 14.4 | 20.3 | 0.0001 |
| COPD | 15.7 | 24.4 | <0.0001 |
| History of cancer | 23.3 | 30.8 | <0.0001 |
| Antithrombotic therapy | |||
| Antiplatelets | 37.0 | 49.1 | <0.0001 |
| Warfarin | 93.4 | 95.0 | 0.14 |
| Dabigatran | 6.6 | 5.2 | 0.18 |
| eGFR<60 mg/dL/1.73 m2 | 34.0 | 48.4 | <0.0001 |
| CHA2DS2-VASC, median (IQR) | 4.0 (3.0–5.0) | 5.0 (4.0–6.0) | <0.0001 |
| HAS-BLED, median (IQR) | 2.0 (1.0–2.0) | 2.0 (2.0–3.0) | <0.0001 |
| ATRIA bleeding score, median (IQR) | 3.0 (1.0–4.0) | 4.0 (3.0–6.0) | <0.0001 |
| Variable . | No major bleed (N = 6830; 92.2%) . | Major bleed (N = 581; 7.8%) . | P-value** . |
|---|---|---|---|
| Demographics | |||
| Age (years) (median) IQR | 75 (67–81) | 78 (71–83) | <0.0001 |
| Male gender | 57.9 | 53.9 | 0.06 |
| White race | 89.4 | 91.6 | 0.06 |
| Comorbidities | |||
| Anaemia/abnormal Hgb/Hct | 34.8 | 57.5 | <0.0001 |
| Hypertension | 84.5 | 89.3 | 0.0019 |
| Diabetes | 30.3 | 33.7 | 0.08 |
| Current smoker | 5.3 | 6.5 | <0.0001 |
| GI bleed | 7.4 | 15.5 | <0.0001 |
| Prior stroke | 9.2 | 13.1 | 0.002 |
| CHF | 33.8 | 44.9 | <0.0001 |
| MI | 15.4 | 20.5 | 0.001 |
| Osteoporosis/hip fracture | 14.4 | 20.3 | 0.0001 |
| COPD | 15.7 | 24.4 | <0.0001 |
| History of cancer | 23.3 | 30.8 | <0.0001 |
| Antithrombotic therapy | |||
| Antiplatelets | 37.0 | 49.1 | <0.0001 |
| Warfarin | 93.4 | 95.0 | 0.14 |
| Dabigatran | 6.6 | 5.2 | 0.18 |
| eGFR<60 mg/dL/1.73 m2 | 34.0 | 48.4 | <0.0001 |
| CHA2DS2-VASC, median (IQR) | 4.0 (3.0–5.0) | 5.0 (4.0–6.0) | <0.0001 |
| HAS-BLED, median (IQR) | 2.0 (1.0–2.0) | 2.0 (2.0–3.0) | <0.0001 |
| ATRIA bleeding score, median (IQR) | 3.0 (1.0–4.0) | 4.0 (3.0–6.0) | <0.0001 |
IQR, interquartile range; hgb, haemoglobin; hct, haematocrit; GI, gastrointestinal; CHF, congestive heart failure; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate.
aPer cent or value.
**P-values from chi-squared tests for categorical variables and Kruskal–Wallis tests for continuous variables.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
